Literature DB >> 28167113

Investigating the potential of Tamarindus indica pectin-chitosan conjugate for reducing recovery period in TNBS induced colitis.

Sheshank Sethi1, Rajneet Kaur Khurana1, Sunil Kamboj1, Radhika Sharma1, Akashdeep Singh1, Vikas Rana2.   

Abstract

The present study was aimed at exploiting the wound healing applications and tablet coating potential of Tamarindus indica pectin-chitosan (PCH) conjugate for reducing recovery period from TNBS induced colitis. The PCH (60:40, 3% w/v) solution when spray coated followed by drying at 50°C created hydrophobic surface, that may be due to interaction of pectin with chitosan as evident from temperature ramping rheological investigations. Further, the 15% w/v coating was sufficient to prevent Mesalamine (Ma) release in pH 1.2. The AUC and AUMC of PCH coated tablets were 1.98 and 17.69 fold increased as compared to uncoated tablets. A synergistic therapeutic effect of PCH conjugate with Ma was evident from the colon/body weight ratio, clinical activity and damage score. Overall, the findings suggested PCH and Ma (20mg) reduces the recovery period from 5 to 4days with reduction in dose.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bioavailability; Coating; Rheology; Tamarind pectin

Mesh:

Substances:

Year:  2017        PMID: 28167113     DOI: 10.1016/j.ijbiomac.2017.01.135

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  2 in total

1.  Ethanol extract and chromatographic fractions of Tamarindus indica stem bark inhibits Newcastle disease virus replication.

Authors:  Omobola O Okoh; Grace E Obiiyeke; Uchechukwu U Nwodo; Anthony I Okoh
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

Review 2.  Pectin Oligosaccharides Ameliorate Colon Cancer by Regulating Oxidative Stress- and Inflammation-Activated Signaling Pathways.

Authors:  Haidong Tan; Wei Chen; Qishun Liu; Guojun Yang; Kuikui Li
Journal:  Front Immunol       Date:  2018-06-27       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.